Spike Glycoprotein, Coronavirus
"Spike Glycoprotein, Coronavirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion.
Descriptor ID |
D064370
|
MeSH Number(s) |
D12.776.543.512.500.665 D12.776.964.970.880.910.665
|
Concept/Terms |
Spike Glycoprotein, Coronavirus- Spike Glycoprotein, Coronavirus
- Coronavirus Spike Glycoprotein
- Spike Protein, Coronavirus
- Coronavirus Spike Protein
- Glycoprotein S, Coronavirus
- Spike Glycoproteins, Coronavirus
|
Below are MeSH descriptors whose meaning is more general than "Spike Glycoprotein, Coronavirus".
Below are MeSH descriptors whose meaning is more specific than "Spike Glycoprotein, Coronavirus".
This graph shows the total number of publications written about "Spike Glycoprotein, Coronavirus" by people in this website by year, and whether "Spike Glycoprotein, Coronavirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2020 | 1 | 0 | 1 |
2021 | 4 | 6 | 10 |
2022 | 3 | 10 | 13 |
2023 | 1 | 1 | 2 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Spike Glycoprotein, Coronavirus" by people in Profiles.
-
Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection. Nat Commun. 2024 Aug 22; 15(1):7240.
-
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive Fc?RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. J Virol. 2024 Jul 23; 98(7):e0067824.
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.
-
Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses. 2023 02 06; 15(2).
-
Maternal-foetal transfer of severe acute respiratory syndrome coronavirus 2 antibodies among women with and those without HIV infection. AIDS. 2022 11 01; 36(13):1777-1782.
-
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. J Virol. 2022 08 10; 96(15):e0055822.
-
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022 09; 28(9):1785-1790.
-
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022 05; 9(5):e309-e322.
-
A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathog. 2022 Apr; 18(4):e1010465.
-
Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. Mol Biol Evol. 2022 Apr 11; 39(4).